Octavia Pickett-Blakely, MD
Gastroenterology · Philadelphia, PANPI 1700941309
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,771 of the $28,834 with a category attached, or 99.8%. Novo Nordisk accounts for 89.9% of it on its own, with 3 other manufacturers making up the rest. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $3203.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$26K
- Ferring Pharmaceuticals AS$3K
- Ironwood Pharmaceuticals, Inc$35
- ERBE USA Inc$10
Across 25 payments — averaging $5022.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vectivbio AG$126K
What the payments were for
- Consulting fees$28,771100%
- Food & beverage$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 6 | $25,919 |
| Ferring Pharmaceuticals AS | 1 | $2,870 |
| Ironwood Pharmaceuticals, Inc | 1 | $35 |
| ERBE USA Inc | 1 | $10 |
How this compares
$28,834 in reported general payments places this provider in the 90th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $330,243 |
| CreonLipase/Protease/Amylase | 35 | $49,411 |
| ZenpepLipase/Protease/Amylase | 17 | $25,342 |
| MotegrityPrucalopride Succinate | 12 | $6,325 |
| Famotidine | 51 | $5,140 |
| Lansoprazole | 24 | $2,498 |
| Magnesium Sulfate | 44 | $1,046 |
| Omeprazole | 58 | $593 |
| LoperamideLoperamide Hcl | 21 | $461 |
| Colestipol Hcl | 14 | $352 |
| Esomeprazole Magnesium | 16 | $329 |
| Ciprofloxacin Hcl | 12 | $264 |
| Pantoprazole Sodium | 22 | $114 |
| Metronidazole | 26 | $110 |
| Ondansetron Hcl | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Gregory GinsbergPhiladelphia$234K
- Neilanjan NandiPhiladelphia$209K
- David LichtensteinPhiladelphia$192K
- Alexander SchlachtermanPhiladelphia$188K
- Kuchikala ReddyPhiladelphia$182K
- James LewisPhiladelphia$175K
- Beth GardnerPhiladelphia$122K
- Gary FalkPhiladelphia$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.